Aflibercept Rescues Vision After Laser for Diabetic Macular Edema

Share this content:
Aflibercept Rescues Vision After Laser for Diabetic Macular Edema
Aflibercept Rescues Vision After Laser for Diabetic Macular Edema

THURSDAY, Dec. 29, 2016 (HealthDay News) -- For eyes experiencing substantial visual loss after macular laser photocoagulation treatment for diabetic macular edema (DME), intravitreal aflibercept improves visual and anatomic outcomes, according to a study published online Dec. 22 in JAMA Ophthalmology.

Charles C. Wykoff, M.D., Ph.D., from Retina Consultants of Houston, and colleagues examined outcomes in 63 of 154 eyes in Study of Intravitreal Aflibercept Injection in Patients With Diabetic Macular Edema (VISTA) and 46 of 133 eyes in Intravitreal Aflibercept Injection in Vision Impairment Due to DME (VIVID). The eyes were initially randomized to laser control and received intravitreal aflibercept injection treatment.

The researchers found that from baseline to week 100, the mean visual gain was 2.2 and 3.8 letters in VISTA and VIVID, respectively. These eyes had a mean loss of 11.0 and 10.0 letters, respectively, from baseline, at the time of initiation of intravitreal aflibercept injection; from the initiation of treatment through week 100, the eyes gained a mean of 17.4 and 13.6 letters, respectively. At the time of intravitreal aflibercept injection initiation, there was a minimal mean change in central subfield thickness from baseline (increase of 3.9 µm in VISTA and decrease of 3.0 µm in VIVID); subsequently, there were further mean reductions of 285.6 and 313.4 µm in VISTA and VIVID, respectively, through week 100.

"Intravitreal aflibercept injection improves visual and anatomic outcomes in eyes experiencing substantial vision loss after macular laser photocoagulation treatment for DME," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Regeneron (the manufacturer of aflibercept) and Bayer HealthCare, both of which funded the VISTA and VIVID trials.

Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA Warns of Possible Heart Risks Linked to Clarithromycin

FDA Warns of Possible Heart Risks Linked to ...

Agency advising doctors to consider prescribing other antibiotics to patients with coronary heart disease

Artificial Intelligence May Help Prevent Physician Burnout

Artificial Intelligence May Help Prevent Physician Burnout

Many potential uses for AI, including improving searches and documentation, selecting treatment

Benzodiazepine Use Declining in Older Adults

Benzodiazepine Use Declining in Older Adults

Findings based on assessment of incidence, prevalence of use in three countries from 2010-2016

is free, fast, and customized just for you!

Already a member?

Sign In Now »